

Patrick M Dillon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7478981/publications.pdf>

Version: 2024-02-01

41
papers

1,847
citations

471509

17
h-index

330143

37
g-index

42
all docs

42
docs citations

42
times ranked

3079
citing authors

#	ARTICLE	IF	CITATIONS
1	Bispecific antibodies for the treatment of breast cancer. Expert Opinion on Biological Therapy, 2022, 22, 1017-1027.	3.1	10
2	A Rare Case of Large-Vessel Vasculitis following Checkpoint Inhibitor Therapy and Pegfilgrastim. Case Reports in Oncological Medicine, 2022, 2022, 1-5.	0.3	6
3	Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy. Frontiers in Oncology, 2022, 12, 801764.	2.8	4
4	Elicestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of Clinical Oncology, 2022, 40, 3246-3256.	1.6	190
5	Genesis of Quality Measurements to Improve the Care Delivered to Patients With Brain Metastases. JCO Oncology Practice, 2021, 17, e397-e405.	2.9	6
6	Pleomorphic adenoma of the breast: A potential morphologic and molecular pitfall in the era of genomic risk stratification. Current Problems in Cancer Case Reports, 2021, 3, 100047.	0.1	2
7	Long-Term Non-progression in Metastatic Breast Cancer Beyond 5 Years: Case Series and Review. Current Breast Cancer Reports, 2021, 13, 208-215.	1.0	2
8	Characterization and Pilot Human Trial of Dedicated Breast Ring Positron Emission Tomography (BRPET) System. Instruments, 2021, 5, 30.	1.8	2
9	Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. Cardio-Oncology, 2020, 6, 21.	1.7	14
10	Efficient dose-finding for drug combination studies involving a shift in study populations. Contemporary Clinical Trials Communications, 2020, 17, 100519.	1.1	2
11	<p>Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data</p>. Breast Cancer: Targets and Therapy, 2020, Volume 12, 69-75.	1.8	10
12	Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. JAMA Oncology, 2019, 5, 1132.	7.1	285
13	Cases and evidence for panel testing in cancer genetics: Is site-specific testing dead?. Journal of Genetic Counseling, 2019, 28, 700-707.	1.6	5
14	Radiographically Occult Carcinomatous Spread of Breast Cancer to the Liver: A Challenging Case. Case Reports in Oncological Medicine, 2019, 2019, 1-5.	0.3	6
15	The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma. American Journal of Surgical Pathology, 2018, 42, 183-191.	3.7	63
16	CONCORD biomarker prediction for novel drug introduction to different cancer types. Oncotarget, 2018, 9, 1091-1106.	1.8	5
17	Early Palliative Care Reduces End-of-Life Intensive Care Unit (ICU) Use but Not ICU Course in Patients with Advanced Cancer. Oncologist, 2017, 22, 318-323.	3.7	51
18	A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma. Clinical Cancer Research, 2017, 23, 4138-4145.	7.0	56

#	ARTICLE	IF	CITATIONS
19	Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, <i>MC1R</i> Status, and Prior Amelanotic Melanoma. JAMA Dermatology, 2017, 153, 1026.	4.1	19
20	Anti-Yo Mediated Paraneoplastic Cerebellar Degeneration Associated with Pseudobulbar Affect in a Patient with Breast Cancer. Case Reports in Oncological Medicine, 2017, 2017, 1-3.	0.3	7
21	A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer. , 2017, 5, 92.		47
22	Orbital Metastases from Breast Cancer: Retrospective Analysis at an Academic Cancer Center. Breast Journal, 2016, 22, 447-450.	1.0	13
23	Cancer treatment-related cardiac toxicity: prevention, assessment and management. Medical Oncology, 2016, 33, 84.	2.5	27
24	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy, 2016, 8, 583-600.	2.0	71
25	Lobular Breast Cancer and Abdominal Metastases: A Retrospective Review and Impact on Survival. Oncology, 2016, 91, 135-142.	1.9	9
26	Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study. Medical Oncology, 2016, 33, 82.	2.5	32
27	Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials. Head and Neck, 2016, 38, 620-627.	2.0	203
28	Role of postoperative radiation therapy in patients with adenoid cystic carcinoma: a SEER analysis. Journal of Radiation Oncology, 2016, 5, 153-159.	0.7	0
29	Longitudinal patterns of cancer patient reported outcomes in end of life care predict survival. Supportive Care in Cancer, 2016, 24, 2217-2224.	2.2	24
30	CARE Track for Advanced Cancer: Impact and Timing of an Outpatient Palliative Care Clinic. Journal of Palliative Medicine, 2016, 19, 57-63.	1.1	51
31	Paraneoplastic neurological complications of breast cancer. Experimental Hematology and Oncology, 2015, 5, 29.	5.0	42
32	Tubular carcinoma of the breast: Institutional and SEER database analysis supporting a unique classification. Breast Disease, 2015, 35, 103-111.	0.8	14
33	Peptide Vaccine: Overview. , 2015, , 1-13.		0
34	Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas. JAMA Dermatology, 2014, 150, 1306.	4.1	142
35	Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer. Journal of the National Cancer Institute, 2014, 106, dju057.	6.3	218
36	A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. , 2014, 2, 23.		21

#	ARTICLE	IF	CITATIONS
37	Delineation of anthracyclines and herceptin induced cardiotoxicity using contrast enhanced CMR. Journal of Cardiovascular Magnetic Resonance, 2014, 16, P278.	3.3	1
38	Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors. Oncologist, 2012, 17, 1303-1316.	3.7	37
39	Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models. Clinical Cancer Research, 2012, 18, 5290-5303.	7.0	118
40	A Mechanistic Study of the Effect of Doxorubicin/Adriamycin on the Estrogen Response in a Breast Cancer Model. Oncology, 2012, 83, 305-320.	1.9	19
41	Catalytic Asymmetric Epoxidation Using a Fructose-Derived Catalyst. Journal of Chemical Education, 2000, 77, 271.	2.3	13